Skip to content

Ligand Pharmaceuticals LGND Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)

Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) at other companies

Corebridge Financial logo
Corebridge FinancialCRBG
$3.32B-0.9%
Wells Fargo & Company logo
Wells Fargo & CompanyWFC
$2.83B+221%
GBC
Glacier BancorpGBCI
$311.13M-41.9%
Bank of Hawaii logo
Bank of HawaiiBOH
$106.6M
Wintrust Financial logo
Wintrust FinancialWTFC
$52.66M-14.6%
Wells Fargo & Company logo
Wells Fargo & CompanyWFC
$2.83B+221%

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's available-for-sale debt securities - amortized cost (due within one year).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's available-for-sale debt securities - amortized cost (due within one year)?
Ligand Pharmaceuticals (LGND) reported available-for-sale debt securities - amortized cost (due within one year) of $351.28M in Q1 2026.
How has Ligand Pharmaceuticals's available-for-sale debt securities - amortized cost (due within one year) changed year-over-year?
Ligand Pharmaceuticals's available-for-sale debt securities - amortized cost (due within one year) increased by 181.1% year-over-year, from $124.95M to $351.28M.